Free Trial

Levi Strauss & Co. (NYSE:LEVI) Receives Outperform Rating from Telsey Advisory Group

Levi Strauss & Co. logo with Retail/Wholesale background

Levi Strauss & Co. (NYSE:LEVI - Get Free Report)'s stock had its "outperform" rating restated by Telsey Advisory Group in a research note issued on Wednesday,Benzinga reports. They presently have a $26.00 target price on the blue-jean maker's stock. Telsey Advisory Group's price target would suggest a potential upside of 47.61% from the stock's previous close.

A number of other equities research analysts have also commented on LEVI. Stifel Nicolaus dropped their price objective on shares of Levi Strauss & Co. from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, October 3rd. Barclays started coverage on shares of Levi Strauss & Co. in a report on Wednesday, January 8th. They set an "overweight" rating and a $24.00 price objective on the stock. Morgan Stanley lowered their price target on shares of Levi Strauss & Co. from $19.00 to $18.00 and set an "equal weight" rating on the stock in a research note on Tuesday. TD Cowen lowered their price target on shares of Levi Strauss & Co. from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, October 3rd. Finally, Citigroup lowered their price target on shares of Levi Strauss & Co. from $21.00 to $19.00 and set a "neutral" rating on the stock in a research note on Friday, January 17th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Levi Strauss & Co. presently has an average rating of "Moderate Buy" and an average price target of $22.30.

Read Our Latest Stock Report on Levi Strauss & Co.

Levi Strauss & Co. Trading Up 0.4 %

Shares of NYSE LEVI traded up $0.07 during midday trading on Wednesday, reaching $17.61. 1,463,387 shares of the stock were exchanged, compared to its average volume of 1,555,645. The business has a 50-day simple moving average of $17.27 and a two-hundred day simple moving average of $18.20. The company has a market capitalization of $6.99 billion, a price-to-earnings ratio of 46.35, a P/E/G ratio of 0.96 and a beta of 1.16. Levi Strauss & Co. has a 12 month low of $15.16 and a 12 month high of $24.34. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.41 and a quick ratio of 0.76.

Insider Buying and Selling at Levi Strauss & Co.

In other news, Director David A. Friedman sold 8,332 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $18.00, for a total value of $149,976.00. Following the completion of the transaction, the director now directly owns 108,344 shares in the company, valued at approximately $1,950,192. The trade was a 7.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.14% of the company's stock.

Hedge Funds Weigh In On Levi Strauss & Co.

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC increased its position in Levi Strauss & Co. by 44.6% during the 3rd quarter. FMR LLC now owns 9,420,007 shares of the blue-jean maker's stock worth $205,356,000 after purchasing an additional 2,907,099 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Levi Strauss & Co. by 2,083.0% in the 2nd quarter. Millennium Management LLC now owns 1,923,206 shares of the blue-jean maker's stock valued at $37,079,000 after purchasing an additional 1,835,107 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Levi Strauss & Co. by 6,794.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,244,873 shares of the blue-jean maker's stock valued at $24,001,000 after purchasing an additional 1,226,818 shares during the last quarter. Marshall Wace LLP boosted its stake in Levi Strauss & Co. by 21.5% during the second quarter. Marshall Wace LLP now owns 4,274,326 shares of the blue-jean maker's stock worth $82,409,000 after acquiring an additional 756,926 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Levi Strauss & Co. by 59.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,555,382 shares of the blue-jean maker's stock worth $33,907,000 after acquiring an additional 579,460 shares in the last quarter. 69.14% of the stock is currently owned by institutional investors and hedge funds.

About Levi Strauss & Co.

(Get Free Report)

Levi Strauss & Co engages in the design, marketing, and sale of apparel products. The company offers jeans, casual and dress pants, tops, shorts, skirts, jackets, footwear, and related accessories. It operates through the following geographical segments: Americas, Europe, and Asia. The company was founded by Levi Strauss in 1853 and is headquartered in San Francisco, CA.

Recommended Stories

Analyst Recommendations for Levi Strauss & Co. (NYSE:LEVI)

Should You Invest $1,000 in Levi Strauss & Co. Right Now?

Before you consider Levi Strauss & Co., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Levi Strauss & Co. wasn't on the list.

While Levi Strauss & Co. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

The Future of Healthcare: 3 AI Stocks Leading the Way

The Future of Healthcare: 3 AI Stocks Leading the Way

2025 promises explosive growth for AI, but which companies are making a difference in healthcare? Chris Markoch highlights three stocks leading the charge.

Recent Videos

Palantir’s Explosive Growth: Buy Now or Wait for a Dip?
5 Stocks to BUY NOW in February 2025
How To Invest in Crypto as A Complete BEGINNER in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines